紫鑫藥業(002118.SZ):荷蘭子公司終止工業大麻合作研究框架協議
格隆匯12月19日丨紫鑫藥業(002118.SZ)公佈,2019年1月9日,公司的荷蘭全資子公司Fytagoras與吉林省農業科學院共同簽訂了《工業大麻合作研究協議》,雙方本着互惠互利、共同發展的精神,經友好協商正式建立合作研發關係,開展工業大麻的研發工作,並計劃以完成大麻品種的CBD含量達10%以上為工作目標。
截止本公告日,吉林省工業大麻尚未合法化,且合法化時間無法預估,雙方簽署的《工業大麻合作研究協議》項下關於對工業大麻品種在國內進行選育、生產技術、產品加工、生物活性成分提取技術等進行研發相關工作無法繼續開展,經合作雙方友好協商,決定終止上述《工業大麻合作研究協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.